| Website | ceregene.com |
| Category | BioTech |
| Phone | 858-458-8800 |
| info@ceregene.com | |
| Employees |
| TOTAL | $39.5M |
| FUNDING TOTAL | $39.5M |
| Series C, 6/07 Investor Growth Capital Alta Partners California Technology Ventures Hamilton BioVentures MPM Capital Cell Genesys | $28M |
| Series D, 11/10 | $11.5M |
Ceregene is a private, San Diego-based biotechnology company focused on the treatment of major neurodegenerative disorders using the delivery of nervous system growth factors. Their clinical programs include CERE-110, an AAV2 based vector expressing nerve growth factor, which is about to enter Phase 2 studies for the treatment of Alzheimer’s disease, and CERE-120, which recently completed a Phase 2 trial in Parkinson’s disease and is currently being evaluated for future development. CERE-135 and CERE-140 are in preclinical development for amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease) and ocular diseases, respectively.
